NEW YORK (GenomeWeb) – Molecular diagnostics company DiaCarta announced today that it has received a $300,000 Phase I Small Business Innovation Research contract from the National Cancer Institute to develop its RadTox QuantiDNA diagnostic into a commercial test for monitoring radiation response in cancer patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.